Bertram L.  Scott net worth and biography

Bertram Scott Biography and Net Worth

Bertram L. Scott serves as a director of BD (Becton, Dickinson and Company), a global medical technology company headquartered in Franklin Lakes, New Jersey. Scott has been a member of the board since 2002.

Scott retired as senior vice president of Population Health of Novant Health in 2019. He previously served as president and chief executive officer (CEO) of Affinity Health Plan, and as president, U.S. Commercial of CIGNA Corporation. Prior thereto, he served as executive vice president of TIAA-CREF and as president and CEO of TIAA-CREF Life Insurance Company. Scott also is a director of Equitable Holdings, Inc. (“EQH”), Lowe’s Companies, Inc. and Dollar Tree, Inc.

Scott adds strong strategic, operational and financial experience to the Board from the variety of executive roles in which he has served during his career. He brings experience in corporate governance and business expertise in the insurance and healthcare fields.

What is Bertram L. Scott's net worth?

The estimated net worth of Bertram L. Scott is at least $6.94 million as of November 7th, 2025. Mr. Scott owns 35,816 shares of Becton, Dickinson and Company stock worth more than $6,936,879 as of December 5th. This net worth approximation does not reflect any other investments that Mr. Scott may own. Learn More about Bertram L. Scott's net worth.

How do I contact Bertram L. Scott?

The corporate mailing address for Mr. Scott and other Becton, Dickinson and Company executives is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. Becton, Dickinson and Company can also be reached via phone at (201) 847-6800 and via email at [email protected]. Learn More on Bertram L. Scott's contact information.

Has Bertram L. Scott been buying or selling shares of Becton, Dickinson and Company?

In the last ninety days, Bertram L. Scott has sold $38,317.86 in shares of Becton, Dickinson and Company stock. Most recently, Bertram L. Scott sold 217 shares of the business's stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a transaction totalling $38,317.86. Following the completion of the sale, the director now directly owns 35,816 shares of the company's stock, valued at $6,324,389.28. Learn More on Bertram L. Scott's trading history.

Who are Becton, Dickinson and Company's active insiders?

Becton, Dickinson and Company's insider roster includes Richard Byrd (EVP and President, Interventional Segment ), Richard Byrd (EVP), Simon Campion (EVP), Alexandre Conroy (EVP), Christopher DelOrefice (Exec. VP & CFO ), Michael Feld (Executive Vice President and President, Life Sciences), Claire Fraser (Director), John Gallagher (VP), Michael Garrison (EVP), Roland Goette (EVP), Jeffrey Henderson (Director), David Hickey (EVP), Patrick Kaltenbach (EVP), Samrat Khichi (EVP), Betty Larson (EVP), James Lim (EVP), Shana Neal (EVP and Chief People Officer), Thomas Polen, Jr. (Insider), Rebecca Rimel (Director), Bertram Scott (Director), David Shan (EVP), and Thomas Spoerel (VP). Learn More on Becton, Dickinson and Company's active insiders.

Are insiders buying or selling shares of Becton, Dickinson and Company?

During the last year, Becton, Dickinson and Company insiders bought shares 1 times. They purchased a total of 1,500 shares worth more than $350,430.00. During the last year, insiders at the medical instruments supplier sold shares 18 times. They sold a total of 17,960 shares worth more than $3,831,767.26. The most recent insider tranaction occured on December, 1st when EVP Michael Feld sold 75 shares worth more than $14,502.00. Insiders at Becton, Dickinson and Company own 0.4% of the company. Learn More about insider trades at Becton, Dickinson and Company.

Information on this page was last updated on 12/1/2025.

Bertram L. Scott Insider Trading History at Becton, Dickinson and Company

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/7/2025Sell217$176.58$38,317.8635,816View SEC Filing Icon  
2/12/2025Sell700$227.99$159,593.0036,033View SEC Filing Icon  
5/18/2015Sell2,160$141.74$306,158.40View SEC Filing Icon  
See Full Table

Bertram L. Scott Buying and Selling Activity at Becton, Dickinson and Company

This chart shows Bertram L Scott's buying and selling at Becton, Dickinson and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Becton, Dickinson and Company Company Overview

Becton, Dickinson and Company logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $193.68
Low: $192.09
High: $194.10

50 Day Range

MA: $188.09
Low: $176.22
High: $195.48

2 Week Range

Now: $193.68
Low: $162.29
High: $251.99

Volume

1,253,147 shs

Average Volume

2,412,403 shs

Market Capitalization

$55.28 billion

P/E Ratio

33.22

Dividend Yield

2.15%

Beta

0.25